Advertisement

Progress in endometrial cancer: Contributions of the former Gynecologic Oncology Group

  • David Scott Miller
    Correspondence
    Corresponding author at: University of Texas Southwestern Medical Center at Dallas, Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, 5323 Harry Hines Blvd., Dallas, TX 75390-9032, United States of America.
    Affiliations
    University of Texas Southwestern Medical Center at Dallas, Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Dallas, TX, United States of America
    Search for articles by this author
  • Marcus E. Randall
    Affiliations
    University of Kentucky, Department of Radiation Medicine, 800 Rose Street, Rm. C114D, Lexington, KY 40536 0293, United States of America
    Search for articles by this author
  • Virginia Filiaci
    Affiliations
    NRG Oncology Statistical and Data Center, Buffalo, NY, United States of America
    Search for articles by this author
Published:January 31, 2020DOI:https://doi.org/10.1016/j.ygyno.2020.01.012

      Highlights

      • The Gynecologic Oncology Group has driven progress in the management of endometrial cancer.
      • These trials have changed surgical, radiation, and chemotherapy practice.
      • Further progress will be seen with targeted and immunologic therapies.

      Abstract

      For over forty years, the Gynecologic Oncology Group drove progress in treating endometrial cancer. The first decades of investigation began with a meticulous prospective, surgicopathologic staging study that was the platform for development of all subsequent trials. The resultant statistical model of low risk, intermediate risk, and high-risk groups of patients led to trials where therapeutic modalities were best targeted at disease spread. A clear role for chemotherapy was established. It was realized that greater advances might be achieved with the advent of newer anti-neoplastic agents and these agents were subjected to extensive phase II testing. These agents later were integrated into comparison trials for advanced endometrial cancer. Multimodality therapy continues to show promise. Hormonal therapy was thoroughly investigated and led to combination hormonal therapy trials. Newer agents, including biologics are under active study, as well as the potential contribution of modern imaging techniques. Finally, GOG0210 established a repository of clinical specimens with detailed clinical and epidemiologic data from patients with surgically staged endometrial carcinoma. This should provide for a much greater understanding of molecular characteristics associated with risk of endometrial cancer recurrence, clinical and histological characteristics, and epidemiologic factors.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Gynecologic Oncology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Creasman W.T.
        • Morrow C.P.
        • Bundy B.N.
        • et al.
        Surgical pathologic spread patterns of endometrial cancer: a Gynecologic Oncology Group study.
        Cancer. 1987; 60: 2035-2041
        • Morrow C.P.
        • Bundy B.N.
        • Kurman R.J.
        • et al.
        Relationship between surgical-pathological risk factors and outcome in clinical stage I and II carcinoma of the endometrium: a Gynecologic Oncology Group study.
        Gynecol. Oncol. 1991; 40: 55-65
        • Creasman W.T.
        • DeGeest K.
        • DiSaia P.J.
        • Zaino R.J.
        Significance of true surgical pathologic staging: a Gynecologic Oncology Group study.
        Am. J. Obstet. Gynecol. 1999; 181: 31-34
        • Zaino R.J.
        Pathologic indicators of prognosis in endometrial adenocarcinoma. Selected aspects emphasizing the GOG experience. Gynecologic Oncology Group.
        Pathol. Annu. 1995; 30: 1-28
        • Zaino R.J.
        • Kurman R.J.
        • Diana K.L.
        • Morrow C.P.
        The utility of the revised International Federation of Gynecology and Obstetrics histologic grading of endometrial adenocarcinoma using a defined nuclear grading system: a Gynecologic Oncology Group study.
        Cancer. 1995; 75: 81-86
        • Zaino R.J.
        • Silverberg S.G.
        • Norris H.J.
        • et al.
        The prognostic value of nuclear versus architectural grading in endometrial adenocarcinoma: a Gynecologic Oncology Group study.
        Int. J. Gynecol. Pathol. 1994; 13: 29-36
        • Pecorelli S.
        Revised FIGO staging for carcinoma of the vulva, cervix, and endometrium.
        Int. J. Gynaecol. Obstet. 2009; 105 (May): 103-104
        • Homesley H.D.
        • Boike G.
        • Spiegel G.W.
        Feasibility of laparoscopic management of presumed stage I endometrial carcinoma and assessment of accuracy of myoinvasion estimates by frozen section: a Gynecologic Oncology Group study.
        Int. J. Gynecol. Cancer. 2004; 14 (PMID: 15086735): 341-347
        • Spirtos N.
        • Eisenkop S.C.
        • Boike G.
        • et al.
        Laparoscopic staging in patients with incompletely staged cancers of the uterus, ovary, fallopian tube, and primary peritoneum: a Gynecology Oncology Group study.
        Am. J. Obstet. Gynecol. 2005; 193 (PMID: 16260204): 1645-1649https://doi.org/10.1016/j.ajog.2005.05.004
        • Walker J.L.
        • Piedmonte M.R.
        • Spirtos N.M.
        • Eisenkop S.M.
        • Schlaerth J.B.
        • Mannel R.S.
        • Spiegel G.
        • Barakat R.
        • Pearl M.L.
        • Sharma S.K.
        Laparoscopy compared with laparotomy for comprehensive surgical staging of uterine cancer: Gynecologic Oncology Group Study (LAP2).
        J. Clin. Oncol. 2009; 27: 5331-5336https://doi.org/10.1200/JCO.2011.38.8645
        • Walker J.L.
        • Piedmonte M.R.
        • Spirtos N.M.
        • et al.
        Recurrence and survival after random assignment to laparoscopy versus laparotomy for comprehensive surgical staging of uterine cancer: Gynecologic Oncology Group LAP2 study.
        J. Clin. Oncol. 2012; 30 (Mar 1): 695-700https://doi.org/10.1200/JCO.2011.38.8645
        • Ramirez P.T.
        • Frumovitz M.
        • Pareja R.
        • Lopez A.
        • Vieira M.
        • Ribeiro R.
        • et al.
        Minimally invasive versus abdominal radical hysterectomy for cervical cancer.
        N. Engl. J. Med. 2018; 379: 1895-1904
        • Creasman W.T.
        • Ali S.
        • Mutch D.G.
        • Zaino R.J.
        • Powell M.A.
        • Mannel R.S.
        • Backes F.J.
        • DiSilvestro P.A.
        • Argenta P.A.
        • Pearl M.L.
        • Lele S.B.
        • Guntupalli S.R.
        • Waggoner S.
        • Spirtos N.
        • Boggess J.F.
        • Edwards R.P.
        • Filiaci V.L.
        • Miller D.S.
        Surgical-pathological findings in type 1 and 2 endometrial cancer: an NRG Oncology/Gynecologic Oncology Group study on GOG-210 protocol.
        Gynecol. Oncol. 2017; 145 (Jun. (Epub 2017 Apr 6. PubMed PMID: 28392124; PubMed Central PMCID: PMC5702929)): 519-525https://doi.org/10.1016/j.ygyno.2017.03.017
        • Zaino R.J.
        • Brady W.E.
        • Todd W.
        • Leslie K.
        • Fischer E.G.
        • Horowitz N.S.
        • Mannel R.S.
        • Walker J.L.
        • Ivanovic M.
        • Duska L.R.
        Histologic effects of medroxyprogesterone acetate on endometrioid endometrial adenocarcinoma: a Gynecologic Oncology Group study.
        Int. J. Gynecol. Pathol. 2014; 33 (Nov. (PubMed PMID: 25272292; PubMed Central PMCID: PMC4533989)): 543-553https://doi.org/10.1097/PGP.0000000000000177
        • Atri M.
        • Zhang Z.
        • Dehdashti F.
        • Lee S.I.
        • Marques H.
        • Ali S.
        • Koh W.J.
        • Mannel R.S.
        • DiSilvestro P.
        • King S.A.
        • Pearl M.
        • Zhou X.
        • Plante M.
        • Moxley K.M.
        • Gold M.
        Utility of PET/CT to evaluate retroperitoneal lymph node metastasis in high-risk endometrial cancer: results of ACRIN 6671/GOG 0233 trial.
        Radiology. 2017; 283 (May. (Epub 2017 Jan 3. PubMed PMID: 28051912; PubMed Central PMCID: PMC5410939)): 450-459https://doi.org/10.1148/radiol.2016160200
        • Thigpen J.T.
        • Buchsbaum H.J.
        • Mangan C.
        • Blessing J.A.
        Phase II trial of Adriamycin in the treatment of advanced or recurrent endometrial carcinoma: a Gynecologic Oncology Group study.
        Cancer Treat. Rep. 1979; 63 (PMID: 369691): 21-27
        • Cohen C.J.
        • Bruckner H.W.
        • Deppe G.
        • et al.
        Multidrug treatment of advanced and recurrent endometrial carcinoma: a Gynecologic Oncology Group study.
        Obstet. Gynecol. 1984; 63 (PMID: 6371627): 719-726
        • Morrow C.P.
        • Bundy B.N.
        • Homesley H.D.
        • et al.
        Doxorubicin as an adjuvant following surgery and radiation therapy in patients with high-risk endometrial carcinoma, stage I and occult stage II: a Gynecologic Oncology Group study.
        Gynecol. Oncol. 1990; 36 (PMID: 2298404): 166-171
        • Thigpen J.T.
        • Blessing J.A.
        • DiSaia P.J.
        • et al.
        A randomized comparison of doxorubicin alone versus doxorubicin plus cyclophosphamide in the management of advanced or recurrent endometrial carcinoma: a Gynecologic Oncology Group study.
        J. Clin. Oncol. 1994; 12 (PMID: 8021731): 1408-1414https://doi.org/10.1200/JCO.1994.12.7.1408
        • Thigpen J.T.
        • Blessing J.A.
        • Lagasse L.D.
        • et al.
        Phase II trial of cisplatin as second-line chemotherapy in patients with advanced or recurrent endometrial carcinoma. A Gynecologic Oncology Group study.
        Am. J. Clin. Oncol. 1984; 7 (PMID: 6539565): 253-256
        • Thigpen J.T.
        • Blessing J.A.
        • Homesley H.
        • et al.
        Phase II trial of cisplatin as first-line chemotherapy in patients with advanced or recurrent endometrial carcinoma: a Gynecologic Oncology Group Study.
        Gynecol. Oncol. 1989; 33: 68-70https://doi.org/10.1016/0090-8258(89)90605-7
        • Thigpen J.T.
        • Brady M.F.
        • Homesley H.D.
        • et al.
        Phase III trial of doxorubicin with or without cisplatin in advanced endometrial carcinoma: a Gynecologic Oncology Group study.
        J. Clin. Oncol. 2004; 22 (PMID: 15459211): 3902-3908https://doi.org/10.1200/JCO.2004.02.088
        • Barrett R.J.
        • Blessing J.A.
        • Homesley H.D.
        • et al.
        Circadian-timed combination doxorubicin-cisplatin chemotherapy for advanced endometrial carcinoma: a phase II study of the Gynecologic Oncology Group.
        Am. J. Clin. Oncol. 1993; 16 (8256764): 494-496
        • Gallion H.H.
        • Brunetto V.L.
        • Cibull M.
        • et al.
        Randomized phase III trial of standard timed doxorubicin plus cisplatin versus circadian timed doxorubicin plus cisplatin in stage III and IV or recurrent endometrial carcinoma: a Gynecologic Oncology Group Study.
        J. Clin. Oncol. 2003; 21: 3808-3813https://doi.org/10.1200/JCO.2003.10.083
        • Thigpen J.T.
        • Blessing J.A.
        • Ball H.
        • Hanjani P.
        • Manetta A.
        • Homesley H.D.
        Hexamethylmelamine as first-line chemotherapy in the treatment of advanced or recurrent carcinoma of the endometrium (a phase II trial of the Gynecologic Oncology Group).
        Gynecol. Oncol. 1988; 31: 435-438
        • Homesley H.
        • Blessing J.A.
        • Sorosky J.
        • Reid G.
        • Look K.Y.
        Phase II trial of liposomal doxorubicin at 40 mg/m2 every four weeks in endometrial carcinoma: a Gynecologic Oncology Group study.
        Gynecol. Oncol. 2005; 98 (15975638): 294-298https://doi.org/10.1016/j.ygyno.2005.05.016
        • Ball H.G.
        • Blessing J.A.
        • Lentz S.S.
        • Mutch D.G.
        A phase II trial of paclitaxel in patients with advanced or recurrent adenocarcinoma of the endometrium: a Gynecologic Oncology Group study.
        Gynecol. Oncol. 1996; 62: 278-281https://doi.org/10.1006/gyno.1996.0227
        • Rose P.G.
        • Blessing J.A.
        • Lewandowski G.A.
        • Creasman W.T.
        • Webster K.D.
        A phase II trial of prolonged oral etoposide (VP-16) as second-line therapy for advanced or recurrent endometrial carcinoma: a Gynecologic Oncology Group study.
        Gynecol. Oncol. 1996; 63: 101-104
        • Lincoln S.
        • Blessing J.A.
        • Lee R.B.
        • Rocereto T.F.
        Activity of paclitaxel as a second-line chemotherapy in endometrial carcinoma.
        Gynecol. Oncol. 2003; 88: 277-281https://doi.org/10.1016/S0090-8258(02)00068-9
        • Muggia F.M.
        • Blessing J.A.
        • Sorosky J.
        • Reid G.C.
        Phase II trial of the pegylated liposomal doxorubicin in previously treated metastatic endometrial cancer: a Gynecologic Oncology Group study.
        J. Clin. Oncol. 2002; 20 (PMID: 11981008): 2360-2364https://doi.org/10.1200/JCO.2002.08.171
        • Miller D.S.
        • Blessing J.A.
        • Lentz S.S.
        • Waggoner S.
        Evaluation of topotecan in the treatment of recurrent or persistent endometrial carcinoma: a Gynecologic Oncology Group study.
        Gynecol. Oncol. 2002; 87: 247-251
        • Garcia A.
        • Blessing J.
        • Nolte S.
        • Mannel R.
        A phase II evaluation of weekly docetaxel (NSC #628503) in the treatment of recurrent or persistent endometrial carcinoma: a Gynecologic Oncology Group study.
        Gynecol. Oncol. 2008; 111 (PMID: 18675446): 22-26https://doi.org/10.1016/j.ygyno.2008.06.013
        • Miller D.S.
        • Blessing J.A.
        • Drake R.D.
        • Higgins R.
        • McMeekin D.S.
        • Puneky L.V.
        • Krasner C.N.
        A phase II evaluation of pemetrexed (ALIMTA, LY231514, IND #40061) in the treatment of recurrent or persistent endometrial carcinoma: a Phase II Study of the Gynecologic Oncology Group.
        Gynecol. Oncol. 2009; 115: 443-446
        • Dizon D.S.
        • Blessing J.A.
        • McMeekin S.
        • Sharma S.K.
        • DiSilvestro P.
        • Alvarez R.D.
        Phase II trial of Ixabepilone as second-line treatment in advanced endometrial cancer: Gynecologic Oncology Group trial 129P.
        J. Clin. Oncol. 2009; 27 (PMID: 19451430 PMCID: PMC2716935): 3104-3108https://doi.org/10.1200/JCO.2008.20.6995
        • Tait D.L.
        • Blessing J.A.
        • Hoffman J.S.
        • Moore K.N.
        • Spirtos N.
        • Lachance J.A.
        • Rotmensch J.
        • Miller D.S.
        A phase II study of gemcitabine (GEMZAR®, LY188011) in the treatment of recurrent or persistent endometrial carcinoma: a Gynecologic Oncology Group study.
        Gynecol. Oncol. 2011; 121: 118-121
        • Fleming G.F.
        • Filiaci V.L.
        • Bentley R.C.
        • et al.
        Phase III randomized trial of doxorubicin + cisplatin versus doxorubicin + 24-h paclitaxel + filgrastim in endometrial carcinoma: a Gynecologic Oncology Group study.
        Ann. Oncol. 2004; 15 (15277255): 1173-1178
        • Fleming G.F.
        • Fowler J.M.
        • Waggoner S.E.
        • et al.
        Phase I trial of escalating doses of paclitaxel combined with fixed doses of cisplatin and doxorubicin in advanced endometrial cancer and other gynecologic malignancies: a Gynecologic Oncology Group study.
        J. Clin. Oncol. 2001; 19 (PMID: 11181665): 1021-1029
        • Fleming G.F.
        • Brunetto V.L.
        • Cella D.
        • et al.
        Phase III trial of doxorubicin plus cisplatin with or without paclitaxel plus filgrastim in advanced endometrial carcinoma: a Gynecologic Oncology Group study.
        J. Clin. Oncol. 2004; 22 (PMID: 15169803): 2159-2166
        • Homesley H.D.
        • Filiaci V.
        • Gibbons S.K.
        • et al.
        A randomized phase III trial in advanced endometrial carcinoma of surgery and volume directed radiation followed by cisplatin and doxorubicin or with or without paclitaxel: a GOG study.
        Gynecol. Oncol. 2009; 112 (Mar): 543-552https://doi.org/10.1016/j.ygyno.2008.11.014
        • Spirtos N.M.
        • Enserro D.
        • Homesley H.D.
        • et al.
        The addition of paclitaxel to doxorubicin and cisplatin and volume-directed radiation does not improve overall survival (OS) or long-term recurrence-free survival (RFS) in advanced endometrial cancer (EC): a randomized phase III NRG/Gynecologic Oncology Group (GOG) study.
        Gynecol. Oncol. 2019; 154 (Epub 2019 Apr 30. PubMed PMID: 31053405): 13-21https://doi.org/10.1016/j.ygyno.2019.03.240
        • Cella D.
        • Huang H.
        • Homesley H.D.
        • Montag A.
        • et al.
        Patient reported peripheral neuropathy of doxorubicin and cisplatin with and without paclitaxel in the treatment of advanced endometrial cancer: results from GOG 184.
        Gynecol. Oncol. 2010; 119: 538-542
        • McMeekin D.S.
        • Filiaci V.L.
        • Thigpen J.T.
        • et al.
        The relationship between histology and outcome in advanced and recurrent endometrial cancer patients participating in first-line chemotherapy trials: a Gynecologic Oncology Group study.
        Gynecol. Oncol. 2007; 106: 16-22https://doi.org/10.1016/j.ygyno.2007.04.032
        • Hoskins P.J.
        • Swenerton K.D.
        • Pike J.A.
        • et al.
        Paclitaxel and carboplatin, alone or with irradiation, in advanced or recurrent endometrial cancer: a phase II study.
        J. Clin. Oncol. 2001; 19: 4048-4053
        • Miller D.
        • Filiaci V.
        • Fleming G.
        • Mannel R.
        • Cohn D.
        • Matsumoto T.
        • Tewari K.
        • DiSilvestro P.
        • Pearl M.
        • Zaino R.
        Randomized phase III noninferiority trial of first line chemotherapy for metastatic or recurrent endometrial carcinoma: a Gynecologic Oncology Group study.
        Gynecol. Oncol. 2012; 125 (Abstract): 771-773https://doi.org/10.1016/j.ygyno.2012.03.034
        • Thipen T.
        • Blessing J.
        • DiSaia P.
        • Ehrlich C.
        Oral medroxyprogesterone acetate in advanced or recurrent endometrial carcinoma: results of therapy in correlation with estrogen and progesterone receptor levels. The GOG experience. Presented at the First International Congress on Cancer and Hormones.
        Endocrinol. Malig. 1986; 446: 454
        • Thigpen J.T.
        • Brady M.F.
        • Alvarez R.D.
        • et al.
        Oral medroxyprogesterone acetate in the treatment of advanced or recurrent endometrial carcinoma: a dose-response study by the Gynecologic Oncology Group.
        J. Clin. Oncol. 1999; 17: 1736-1744
        • Lentz S.S.
        • Brady M.F.
        • Major F.J.
        • et al.
        High-dose megestrol acetate in advanced or recurrent endometrial carcinoma: a Gynecologic Oncology Group Study.
        J. Clin. Oncol. 1996; 14 (PMID: 8636744): 357-361
        • Thigpen T.
        • Brady M.F.
        • Homesley H.D.
        • et al.
        Tamoxifen in the treatment of advanced or recurrent endometrial carcinoma: a Gynecologic Oncology Group study.
        J. Clin. Oncol. 2001; 19 (PMID: 11208827): 364-367
        • Whitney C.W.
        • Brunetto V.L.
        • Zaino R.J.
        • et al.
        Phase II study of medroxyprogesterone acetate plus tamoxifen in advanced endometrial carcinoma: a Gynecologic Oncology Group study.
        Gynecol. Oncol. 2004; 92: 4-9https://doi.org/10.1016/j.ygyno.2003.09.018
        • Singh M.
        • Zaino R.J.
        • Filiaci V.J.
        • Leslie K.K.
        Relationship of estrogen and progesterone receptors to clinical outcome in metastatic endometrial carcinoma: a Gynecologic Oncology Group study.
        Gynecol. Oncol. 2007; 106: 325-333https://doi.org/10.1016/j.ygyno.2007.03.042
        • Florica J.V.
        • Brunetto V.L.
        • Hanjani P.
        • et al.
        Phase II trial of alternating courses of megestrol acetate and tamoxifen in advanced endometrial carcinoma: a Gynecologic Oncology Group.
        Gynecol. Oncol. 2004; 91: 10-14https://doi.org/10.1016/j.ygyno.2003.11.008
        • Rose P.G.
        • Brunetto V.L.
        • VanLe L.
        • Bell J.
        • Walker J.L.
        • Lee R.B.
        A phase II trial of anastrozole in advanced recurrent or persistent endometrial cancer: a Gynecologic Oncology Group study.
        Gynecol. Oncol. 2000; 78: 212-216https://doi.org/10.1006/gyno.2000.5865
        • Covens A.L.
        • Filliaci V.
        • Gersell D.
        • et al.
        Phase II study of fulvestrant in recurrent/metastatic endometrial carcinoma: a Gynecologic Oncology Group study.
        Gynecol. Oncol. 2010; 120: 185-188https://doi.org/10.1016/j.ygyno.2010.10.015
        • Aghajanian C.
        • Sill M.W.
        • Darcy K.M.
        • Greer B.
        • McMeekin D.S.
        • Rose P.G.
        • Rotmensch J.
        • Barnes M.N.
        • Hanjani P.
        • Leslie K.K.
        Phase II trial of bevacizumab in recurrent or persistent endometrial cancer: a Gynecologic Oncology Group study.
        J. Clin. Oncol. 2011; 29: 2259-2265https://doi.org/10.1200/JCO.2010.32.6397
        • Bender D.
        • Sill M.W.
        • Lankes H.A.
        • Reyes H.D.
        • Darus C.J.
        • Delmore J.E.
        • Rotmensch J.
        • Gray H.J.
        • Mannel R.S.
        • Schilder J.M.
        • et al.
        A phase II evaluation of cediranib in the treatment of recurrent or persistent endometrial cancer: an NRG Oncology/Gynecologic Oncology Group study.
        Gynecol. Oncol. 2015; 138 (Sep. (Epub 2015 Jul 15. PubMed PMID: 26186911; PubMed Central PMCID: PMC4642817)): 507-512https://doi.org/10.1016/j.ygyno.2015.07.018
        • Fleming G.F.
        • Filiaci V.L.
        • Marzullo B.
        • Zaino R.J.
        • Davidson S.A.
        • Pearl M.
        • Makker V.
        • Burke 2nd, J.J.
        • Zweizig S.L.
        • Van Le L.
        • Hanjani P.
        • Downey G.
        • Walker J.L.
        • Reyes H.D.
        • Leslie K.K.
        Temsirolimus with or without megestrol acetate and tamoxifen for endometrial cancer: a gynecologic oncology group study.
        Gynecol. Oncol. 2014; 132 (Mar. (PubMed PMID: 24456823; PubMed Central PMCID: PMC4063288)): 585-592https://doi.org/10.1016/j.ygyno.2014.01.015
        • Slomovitz B.M.
        • Filiaci V.L.
        • Coleman R.L.
        • Walker J.L.
        • Fleury A.C.
        • Holman L.L.
        • Miller D.S.
        GOG 3007, a randomized phase II (RP2) trial of everolimus and letrozole (EL) or hormonal therapy (medroxyprogesterone acetate/tamoxifen, PT) in women with advanced, persistent or recurrent endometrial carcinoma (EC): a GOG Foundation study.
        Gynecol. Oncol. 2018; 146: 2https://doi.org/10.1016/j.ygyno.2018.04.012
        • Aghajanian C.
        • Filiaci V.
        • Dizon D.S.
        • Carlson J.W.
        • Powell M.A.
        • Secord A.A.
        • Tewari K.S.
        • Bender D.P.
        • O’Malley D.M.
        • Stuckey A.
        • Gao J.
        • Dao F.
        • Soslow R.A.
        • Lankes H.A.
        • Moore K.
        • Levine D.A.
        A phase II study of frontline paclitaxel/carboplatin/bevacizumab, paclitaxel/carboplatin/temsirolimus, or ixabepilone/carboplatin/bevacizumab in advanced/recurrent endometrial cancer.
        Gynecol. Oncol. 2018; 150 (Aug. (Epub 2018 May 24. PubMed PMID: 29804638; PubMed Central PMCID: PMC6179372)): 274-281https://doi.org/10.1016/j.ygyno.2018.05.018
        • Keys H.M.
        • Roberts J.A.
        • Brunetto V.L.
        • et al.
        A phase III trial of surgery with or without adjunctive external pelvic radiation therapy in intermediate risk endometrial adenocarcinoma: a Gynecologic Oncology Group study.
        Gynecol. Oncol. 2004; 92: 744-751https://doi.org/10.1016/j.ygyno.2003.11.048
        • Sutton G.
        • Axelrod J.H.
        • Bundy B.N.
        • et al.
        Whole abdominal radiotherapy in the adjuvant treatment of patients with stage III and IV endometrial cancer: a Gynecologic Oncology Group study.
        Gynecol. Oncol. 2005; 97: 755-763https://doi.org/10.1016/j.ygyno.2005.03.011
        • Randall M.E.
        • Filiaci V.L.
        • Muss H.
        • et al.
        Randomized phase III trial of whole-abdominal irradiation versus doxorubicin and cisplatin chemotherapy in advanced endometrial carcinoma: a Gynecologic Oncology Group study.
        J. Clin. Oncol. 2006; 24 (Jan 1. PMID: 16330675): 36-44
        • Reisinger S.A.
        • Asbury R.
        • Liao S.Y.
        • Homesley H.D.
        A phase I study of weekly cisplatin and whole abdominal radiation for the treatment of stage III and IV endometrial carcinoma: a Gynecologic Oncology Group pilot study.
        Gynecol. Oncol. 1996; 63: 299-303https://doi.org/10.1006/gyno.1996.0326
        • McMeekin D.S.
        • Walker J.J.
        • Hartenbach E.M.
        • Bookman M.A.
        • Koh W.-J.
        Phase I trial of the treatment of high-risk endometrial cancer with concurrent weekly paclitaxel and cisplatin and whole abdominal radiation therapy: a Gynecologic Oncology Group study.
        Gynecol. Oncol. 2009; 112: 134-141https://doi.org/10.1016/j.ygyno.2008.09.015
        • Randall M.E.
        • Filiaci V.
        • McMeekin D.S.
        • et al.
        Phase III trial: adjuvant pelvic radiation therapy versus vaginal brachytherapy plus paclitaxel/carboplatin in high-intermediate and high-risk early stage endometrial cancer.
        J. Clin. Oncol. 2019; 37: 1810-1818https://doi.org/10.1200/JCO.18.01575
        • Matei D.
        • Filiaci V.
        • Randall M.E.
        • Mutch D.
        • Steinhoff M.M.
        • DiSilvestro P.A.
        • Moxley K.M.
        • Kim Y.M.
        • Powell M.A.
        • O'Malley D.M.
        • Spirtos N.M.
        • Small W.
        • Tewari K.S.
        • Richards W.E.
        • Nakayama J.
        • Matulonis U.A.
        • Huang H.Q.
        • Miller D.S.
        Adjuvant chemotherapy plus radiation for locally advanced endometrial cancer.
        N. Engl. J. Med. 2019; 380: 2317-2326https://doi.org/10.1056/NEJMoa1813181
        • Barakat R.R.
        • Bundy B.N.
        • Spirtos N.M.
        • et al.
        Randomized double-blind trial of estrogen replacement therapy versus placebo in stage I or II endometrial cancer: a Gynecologic Oncology Group Study.
        J. Clin. Oncol. 2006; 24 (Feb 1. PMID: 16446331): 587-592